China, Aug. 19 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase Ib Study of HDM2020 in Patients with Advanced Pulmonary Squamous Cell Carcinoma with High Expression of FGFR2b'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600130320
Registration Time: 2026/08/18
Type: Interventional study
Primary Sponsor: Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=307216
Published by HT Digital Content Services with permission from Health Daily Digest....